Inside Information: BEXMAB Phase II trial met its primary endpoint in treatment-resistant High Risk MDS (r/r HR MDS) Topline read-out from the Phase II BEXMAB trial confirms earlier positive findings ...

急性髓系白血病（AML）常见于老年患者，高强度化疗预后不佳。研究人员开展了低强度治疗的系统性回顾和网络荟萃分析。结果显示，AZA + VEN、LDAC + glasdegib 等方案疗效突出。该研究为老年 AML 患者治疗提供依据，意义重大。

TURKU, FI / ACCESS Newswire / April 15, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Inside Information: BEXMAB Phase II trial met its primary endpoint in treatment-resistant High Risk MDS (r/ ...

Background: Azacitidine is used to treat myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It acts as a cytosine analog and DNA methyltransferase inhibitor, inducing DNA hypomethylation ...

Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in ...

A phase 3 study is ongoing to confirm the survival benefit of venetoclax plus azacitidine in patients with treatment-naive high-risk MDS. The combination of venetoclax plus azacitidine was well ...

Associate Health Minister with responsibility for Pharmac David Seymour, and Health Minister Simeon Brown welcome Pharmac’s ...

Historically, BPDCN treatment relied on chemotherapy regimens adapted from leukemia or lymphoma protocols. However, recent breakthroughs have transformed the treatment paradigm. ELZONRIS (Stemline ...

SLS009 is associated with an improvement in survival among patients with relapsed/refractory acute myeloid leukemia.

Median Overall Survival (mOS) in Patients with AML-Myelodysplasia-Related Changes (AML-MRC) and 8.8 mOS in All Relapsed or ...

A new study has now provided key insights into how continued treatment with azacitidine can help extend remission periods in elderly patients with acute myeloid leukemia, a type of blood cancer ...